TIDMRUA

RNS Number : 8096V

RUA Life Sciences PLC

16 December 2021

RUA Life Sciences plc

("RUA", the "Company" or the "Group")

Unaudited Interim Results

RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon (TM) ) , today announces its unaudited interim results for the six months ended 30 September 2021.

Highlights:

   --      12% increase in Revenues to GBP708,000 (H1 2020: GBP631,000) 
   --      Continued investment in R&D activities 

-- Strong cash position at GBP4.8 million (30 September 2020: GBP1.0 million, 31 March 2021: GBP6.3 million)

   --      Investment in capital equipment for business expansion 
   --      Strengthened senior management team 
   --      Delay in regulatory process of graft approval (as previously announced) 
   --      Continued progress on heart valve project 

Bill Brown, Chairman of RUA Life Sciences, commented:

"The change to the regulatory process for the vascular graft range is clearly a major disappointment for both the Company and its shareholders. We remain confident that approval remains a question of "when" and not "if". Progress in the other parts of the business remains on track."

For further information contact:

RUA Life Sciences

Bill Brown, Chairman Tel: +44 (0)1294 317073

David Richmond, CEO Tel: +44 (0)1294 317073

   Shore Capital (Nominated Adviser and Joint Broker)           Tel: +44 (0)20 7408 4080 

Tom Griffiths/David Coaten

   Cenkos Securities plc (Joint Broker)                                  Tel: +44 (0)20 7397 8900 

Max Gould (Corporate Finance)

Michael Johnson (Sales)

About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-Eon (TM) , the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-Eon (TM) , manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.

Elast-Eon(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 7 million implants and 14 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.

The Group's four business units are:

 
 RUA Medical        End-to-end contract developer and manufacturer 
  :                  of medical devices and implantable fabric specialist. 
 RUA Biomaterials   Licensor of Elast-Eon (TM) polymers to the medical 
  :                  device industry. 
 RUA Vascular:      Development of large bore polymer sealed grafts 
                     and soft tissue patches. 
 RUA Structural     Development of tri leaflet polymeric heart valves. 
  Heart : 
 

A copy of this announcement will be available shortly at www.rualifesciences.com/investor-relations/regulatory-news-alerts .

CHAIRMAN'S STATEMENT

I set out below an overview of the unaudited consolidated interim results of RUA Life Sciences Plc for the six months to 30 September 2021 together with an update on more recent progress and events. The period has been one of continued investment in the business and the new product pipeline in particular.

Unaudited interim results for the six months to 30 September 2021

The results set out below have consolidated the results of RUA Medical Devices Limited with the polymer licensing business and the R&D pipeline activities of the group. Total revenues reported of GBP708,000 represents an increase of 12% over the same period in the previous year. Third party contract manufacturing revenues increased 33% year on year to GBP552,000 reflecting bounce back in elective surgeries, particularly in the US. Polymer license and royalty fees represented the balance of group revenues of GBP156,000. This figure is around GBP60,000 down on the previous year but disguises a growth in the underlying volumes of Elast-Eon(TM) being shipped by our manufacturing licensee, and is masked by an adverse exchange movement and a timing difference in the periods in which, as previously announced, royalties from a major licensee will be recognised in this financial year. We anticipate this timing difference to reverse during the second half of the current finncial year. The reduction in other income from GBP239,000 to GBP37,000 is represented by a Covid support grant of GBP150,000 received last year together with some employees having been furloughed in that year.

RUA continued to expense all R&D investment through its profit and loss account rather than capitalise the investment. R&D costs are included in administrative expenses which amounted to GBP1,658,000 during the period, an increase of GBP149,000 over the preceding six month period which in turn was GBP328,000 higher than the first half of last year. R&D expenditure during the half year amounted to some GBP515,000, a doubling of the run rate last year.

Overall, the increased loss before tax for the period of GBP1,315,000 (2020: GBP622,000) is attributed to a combination of increased R&D activities, further investment in the infrastructure to support growth and the reduction in Covid grant support.

The Group retains a cash balance at the period end of GBP4,763,000 (2020: GBP1,009,000) having invested further in capital equipment and made the final payment of the deferred consideration payable for the acquisition of RUA Medical.

RUA Vascular - Regulatory Strategy

The focus over the period was concluding a not inconsiderable amount of work required in preparation for the recent 510(k) regulatory submission to the FDA for the range of Elast-Eon(TM) sealed vascular grafts.

The regulatory strategy and testing protocols were set in September 2020 under advice from third party consultants. Much was asked of the RUA team to achieve the demanding timelines for each of product design, development and regulatory testing and these activities were carried out in only 18 months from the acquisition of RUA Medical.

The Company announced in early November 2021 that the 510(k) for the vascular graft range had been submitted to the FDA, but was disappointed to have to announce on 13 December 2021 a delay to the regulatory process. The initial document review has been concluded by the FDA and a lead reviewer appointed. A call was held with the FDA to discuss the Company's submission.

The 510(k) strategy sought approval based on the Company's claim that its device is substantially equivalent to existing products on the market. Having provisionally reviewed the Company's application, the FDA has highlighted that the Company's products introduce novel technology which is unproven in this application, i.e. the incorporation of Elast-Eon(TM) on the outside of the graft to ensure that it is sealed. The standard of data required to support the 510(k) is therefore higher than if the Company was producing a true like-for-like product. The FDA has indicated that it will require human clinical data in order to approve the Company's product. Rather than withdraw the 510(k), the Company has mutually agreed with the FDA to convert its 510(k) submission to a pre-submission or Q-sub. This Q-sub is an interactive discussion between RUA and the FDA to determine the regulatory pathway to approval in the US and allows the Company to negotiate with the FDA over the data required to support a future 510(k) clearance. Through this route, the Company will receive a full written response from the FDA in January 2022, which will allow detailed discussions to take place thereafter with the FDA.

Until the written response is received from the FDA, and the additional data requirements understood, it is not currently possible to provide accurate guidance on the revised regulatory pathway.

It is however clear that human clinical data will be required for FDA clearance to enable the Company to market the grafts. It had always been in our plans to undertake a trial or study once 510(k) clearance had been received. This was planned for marketing and regulatory reasons. From a marketing perspective, US based surgeons and hospitals, other than the Key Opinion Leaders, would wish to see clinical data to support the acceptance cascade of the new device. Additionally, the second target market after the US was planned to be Europe and the regulatory requirements for CE Mark approval necessitates a clinical study.

The revised process will result in an acceleration of the Company's clinical study plans that will serve us well in the long run, by enabling an earlier entry into European and other global markets and providing Sales and Marketing teams with the required clinical data at US market launch to accelerate and drive acceptance and take up of the products.

RUA Vascular - Market Drivers and Production Capacity

Production capacity was being developed to be capable of meeting the market needs of initial marketing samples and provision of clinical devices for the clinical studies, with the scale up production equipment being verified for manufacture to meet the growing demand as study results became available. Additionally, the initial launch would target straight grafts with the aortic root graft to follow.

Over the last few months, the Company has been actively engaged with the surgical and medical device community in both Europe and the USA. This has involved a number of potential substantial OEM companies, carefully chosen European distribution partners plus a lead US importer with experienced US distribution partners. In all cases, the Company has been able to provide product samples and the feedback is now resulting in positive changes to launch plans.

It has become clear that there is an acceptance in the medical and device community of an inevitable switch away from animal sourced products once a surgical fully synthetic graft is available. The opportunity open to RUA is now much more than being just another graft manufacturer with an interesting sealing technology, but to become a very significant player in the surgical graft market. The market has seen little innovation in new surgical graft technology, with most companies focussing on endovascular products whilst continuing to enjoy attractive margins from surgical grafts. RUA has the potential to disrupt this market.

The structural shift towards non-biogenically sealed grafts will happen in Europe too and the Company has observed substantial interest in the product range from surgeons, OEM manufacturers and distribution partnerships. The Company therefore needs to accelerate its work on obtaining regulatory approval for the RUA grafts in Europe where a clinical trial will be required.

There is growing OEM interest in the RUA graft range and the unique one-piece aortic root graft in particular. Not only does the RUA product offer several potential benefits to surgeons, but it provides clear advantages in both manufacturing and sterilising valved conduits. Such are the surgical benefits of combining a graft with a valve, the selling prices of the combined product can be almost double the selling prices of the individual components. Asking a medical device company to change supplier of a key device component is not a simple task due to the regulatory process it will need to go through. With the growing recognition of supply chain risk, the manufacturing benefits of a polymer sealed graft and surgeon impetus, the Board believes that the RUA graft has a significant opportunity for valved conduits.

Aortic root grafts are of much greater added value than the standard straight grafts and as such retail at two to three times the value of a corresponding straight graft.

The anticipated requirement to undertake a clinical study for 510(k) clearance to market not only accelerates the timeframe for a European market launch, but also provides the marketing data to help drive faster market acceptance in the US once approved. The market feedback on the aortic root grafts also helps the Company's manufacturing and production plans to ensure that the higher value products are prioritised for sale once the vascular graft range has received regulatory approval.

RUA Medical

A recent review of the resources available to RUA Medical and competing demands for those resources from group wide development plans has resulted in a slight change to RUA Medical's business model to ensure that priority is given to long term strategic opportunities that can add a minimum of 10 per cent. to RUA Medical revenues together with Group projects.

In line with this revised strategy, RUA Medical has been involved in a long running development project for a global medical device company. The time invested in this project has resulted in a new income stream from manufacturing medical textile components, which is expected to commence in the second half of this financial year and once fully on stream should meet the incremental revenue requirements under the revised strategy.

Sales to the major customer of RUA Medical continue to recover from Covid related elective surgery deferment. Order intake is currently displaying an unusual level of variability making forecasting the level of growth difficult.

RUA Biomaterials

The Company's manufacturing partner, Biomerics, is currently undertaking an expansion of its Elast-Eon(TM) manufacturing capacity and is further increasing marketing activities relating to its polymer offering. Deliveries of polymer to Biomerics customers have seen continued growth over the last few months. It is also pleasing to report that RUA's Intellectual Property portfolio has been enhanced with the granting of a new European patent titled: "Process for the preparation of polyurethane solutions based on silicon-polycarbonate diols."

RUA Structural Heart

The heart valve projects have continued to make good progress with recent manufacturing trials of the 100% polymeric leaflet demonstrating a step change in quality of manufacture and durability potential. The results from those manufacturing trials have confirmed the predictive modelling undertaken prior to the trial thus giving additional confidence that further design and process improvements should again be achieved in manufacture. This valve leaflet low stress design has been replicated utilising a composite material and given the promising results in hydro dynamic testing of the early proof of concept devices, equipment is now being commissioned to manufacture composite valves in a controlled environment. Polymers and non-biogenic valve options are now being openly discussed at influential global cardiothoracic surgical meetings as being the future of heart valves and RUA is being mentioned in those discussions. The Company's strategy is to develop the two technology platforms in parallel to the point of determining the most clinically viable.

Planning for Growth

A little over 18 months ago, the Group acquired RUA Medical which, at the time, was a third-party medical device manufacturer with a focus on new product innovation. While the Group has benefitted from this innovative culture, it must also continue to develop the scale and expertise to meet the needs of a device manufacturer in its own right. The Company recently acquired the industrial unit next door to the Irvine facility and plans are being drawn up to develop a further range of clean room suites required to meet the likely demand for the Company's grafts.

The Board also recognises the need to build the team and I am delighted that the senior executive team at RUA Life Sciences has been further strengthened by two key appointments. Iain Anthony has joined as Director of Clinical and Regulatory Affairs, a non-Board position, and brings a wealth of relevant cardiovascular device experience. In addition, Lachlan Smith has joined as CFO with expertise in implementing the financial and management systems required to control high growth businesses. Subject to the completion of satisfactory due diligence, expected to be completed in January 2022, the Company intends to appoint Lachlan to the Board and will make a further announcement in due course. Both Iain and Lachlan have key roles to play in the business in providing the expertise to lead the revised regulatory strategy and the detailed financial planning to maximise contribution from the vascular range by prioritising both manufacturing efforts and sales focus.

Outlook

It is clearly a disappointment that the 510(k) regulatory path was not as simple as we had hoped and been advised. It is however a relief that the issues relate to substantive equivalence rather than the market need or benefits of the graft range. Rather than obtain US marketing clearance and undertake a soft launch as clinical data is gathered, the clinical data will now be gathered ahead of regulatory approval allowing a fuller launch into both the US and Europe supported with greater clinical evidence available for OEM partners.

The Company will continue to update on its plans as discussions progress with the FDA and it has a clearer view on the likely work packages required and timeframes.

Bill Brown, Chairman

15 December 2021

CONDENSED CONSOLIDATED INTERIM INCOME STATEMENT

Six months ended 30 September 2021

 
                                        Unaudited    Unaudited         Audited 
                                       Six months   Six months   Twelve months 
                                        to 30 Sep    to 30 Sep       to 31 Mar 
                                             2021         2020            2021 
                                Note     GBGBP000     GBGBP000        GBGBP000 
                                      -----------  -----------  -------------- 
 Revenue                         3            708          631           1,528 
 Cost of sales                              (180)        (134)           (276) 
                                      -----------  -----------  -------------- 
 Gross profit                                 528          497           1,252 
 Other income                                  37          239             279 
 Administrative expenses                  (1,658)      (1,181)         (2,690) 
 Other expenses: 
 Share-based payments                        (68)            -           (128) 
 Bad debts written back                         -            -               8 
 Depreciation & amortisation                (145)        (175)           (272) 
                                      -----------  -----------  -------------- 
 Total adimistrative 
  expenses                                (1,871)      (1,356)         (3,082) 
                                      -----------  -----------  -------------- 
 Operating loss                           (1,306)        (620)         (1,551) 
 Finance income/(expense)                     (9)          (2)            (43) 
                                      -----------  -----------  -------------- 
 Loss before taxation                     (1,315)        (622)         (1,594) 
 Taxation                                       4           13             143 
                                      -----------  -----------  -------------- 
 Loss attributable to 
  equity holders of the 
  parent company                          (1,311)        (609)         (1,451) 
                                      -----------  -----------  -------------- 
 Loss per share (basic 
  and diluted) - GB Pence        1         (5.91)       (3.76)          (8.20) 
 

CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION

 
                                         Unaudited   Unaudited       Audited 
                                            30 Sep      30 Sep 
                                              2021        2020   31 Mar 2021 
                                  Note    GBGBP000    GBGBP000      GBGBP000 
 Assets 
 Non-current assets 
 Goodwill                          4           301           -           301 
 Other intangible assets           5           547       1,013           574 
 Property, plant and 
  equipment                        6         2,231       1,630         1,952 
                                        ----------  ----------  ------------ 
 Total non-currents 
  assets                                     3,079       2,643         2,827 
                                        ----------  ----------  ------------ 
 
 Current assets 
 Inventories                                   177         114            85 
 Trade and other receivables                   866         278           949 
 Cash and cash equivalents                   4,763       1,009         6,294 
                                        ----------  ----------  ------------ 
 Total current assets                        5,806       1,401         7,328 
                                        ----------  ----------  ------------ 
 
 Total assets                                8,885       4,044        10,155 
                                        ----------  ----------  ------------ 
 
 Equity 
 Issued capital                    7         1,109      12,650        12,949 
 Share premium                              11,729       5,554        11,729 
 Capital redemption 
  reserve                          7        11,840           -             - 
 Other reserve                             (1,629)     (1,825)       (1,697) 
 Profit and loss account                  (15,786)    (13,633)      (14,475) 
                                        ----------  ----------  ------------ 
 Total equity attributable 
  to equity holders of 
  the parent company                         7,263       2,746         8,506 
                                        ----------  ----------  ------------ 
 
 Liabilities 
 Non-current liabilities 
 Borrowings                                    305         270           223 
 Lease liabilities                               5          20           124 
 Deferred tax                                  159         118           163 
 Other Liabilities                             204          50            40 
                                        ----------  ----------  ------------ 
 Total non-current liabilities                 673         458           550 
                                        ----------  ----------  ------------ 
 
 Current liabilities 
 Borrowings                                     60          10            23 
 Lease liabilities                               8           8            40 
 Trade and other payables                      847         802         1,016 
 Other liabilities                              34          20            20 
                                        ----------  ----------  ------------ 
 Total current liabilities                     949         840         1,099 
                                        ----------  ----------  ------------ 
 
 Total liabilities                           1,622       1,298         1,649 
                                        ----------  ----------  ------------ 
 
 Total equity and liabilities                8,885       4,044        10,155 
                                        ----------  ----------  ------------ 
 

At 30 September 2021

 
                                           Unaudited    Unaudited         Audited 
                                          Six months   Six months   Twelve months 
                                               to 30        to 30       to 31 Mar 
                                            Sep 2021     Sep 2020            2021 
                                            GBGBP000     GBGBP000        GBGBP000 
 Cash flows from operating activities 
 Group loss after tax                        (1,311)        (609)         (1,451) 
 Adjustments for: 
 Fair value gain on acquisition                    -         (21)               - 
  of subsidiary 
 Other / rounding                                  -            2               - 
 Depreciation and amortisation                   145          175             272 
 Share-based payments                             68            -             128 
 Interest (income) / expense                       7            2               9 
 Tax credit in year                                -            -           (143) 
 (Increase) / decrease in trade 
  and other receivables                          563         (44)           (589) 
 (Increase) / decrease in inventories           (93)            -               7 
 Increase / (decrease) in taxation               (4)         (13)             122 
 Increase / (Decrease) in trade 
  and other payables                           (471)         (47)             231 
 Net cash flow from operating 
  actvities                                  (1,096)        (555)         (1,414) 
                                         -----------  -----------  -------------- 
 
 Cash flows from investing activites 
 Purchase of property, plant & 
  equipment                                    (397)        (310)           (620) 
 Proceeds from disposal of property 
  plant and equipment                              -            -              18 
 Acquisition of subsidiary, net 
  of cash acquired                                 -        (354)           (341) 
 Interest received / (paid)                      (7)          (1)             (9) 
                                         -----------  -----------  -------------- 
 Net cash flow from investing 
  activities                                   (404)        (665)           (952) 
                                         -----------  -----------  -------------- 
 
 Cash flows from financing activities 
 Proceeds of issue of share capital, 
  net of issue costs                               -            -           6,462 
 Proceeds from borrowing                           -          260             260 
 Repayment of loans and lease 
  liabilities                                   (31)          (7)            (38) 
 Net cash flow from financing 
  activities                                    (31)          253           6,684 
                                         -----------  -----------  -------------- 
 
 Net increase / (decrease) in 
  cash and cash equivalents                  (1,531)        (967)           4,318 
 Cash and cash equivalents at 
  beginning of period                          6,294        1,976           1,976 
                                         -----------  -----------  -------------- 
 Cash and cash equivalents at 
  end of period                                4,763        1,009           6,294 
                                         -----------  -----------  -------------- 
 

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENT

 
Six months ended 30 September 2021 
Condensed consolidated interim statement of changes in equity 
 
                                       Issued                      Capital                Profit 
                                        share                   redemption      Other   and loss      Total 
                                      capital  Share premium       reserve    reserve    account     equity 
                                     GBGBP000       GBGBP000      GBGBP000   GBGBP000   GBGBP000   GBGBP000 
Balance at 31 March 2020               12,574          4,550             -    (1,825)   (13,024)      2,275 
Rounding                                    1              -             -          -          -          1 
Issue of equity share capital 
 (net of issue costs)                      75          1,004             -          -          -      1,079 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
Transactions with owners                   76          1,004             -          -          -      1,080 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
Total comprehensive loss 
 for the period                             -              -             -          -      (609)      (609) 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
Balance at 30 September 2020           12,650          5,554             -    (1,825)   (13,633)      2,746 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
Rounding                                  (1)              -             -          -          -        (1) 
Share-based payments                        -              -             -        128          -        128 
Issue of equity share capital 
 - exercise of warrants                     8             42             -          -          -         50 
Issue of equity share capital 
 (net of issue costs) - fundraise         292          6,133             -          -          -      6,425 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
Transactions with owners                  299          6,175             -        128          -      6,602 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
Total comprehensive loss 
 for the period                             -              -             -          -      (842)      (842) 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
Balance at 31 March 2021               12,949         11,729             -    (1,697)   (14,475)      8,506 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
Transfer deferred share to 
 capital redemption reserve          (11,840)              -        11,840          -          -          - 
Share-based payments                        -              -             -         68          -         68 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
Transactions with owners             (11,840)              -        11,840         68          -         68 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
Total comprehensive loss 
 for the period                             -              -             -          -    (1,311)    (1,311) 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
Balance at 30 September 2021            1,109         11,729        11,840    (1,629)   (15,786)      7,263 
                                    ---------  -------------  ------------  ---------  ---------  --------- 
 
 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

   1.   BASIS OF PREPARATION 

General information

RUA Life Sciences plc is the ultimate parent company of the Group, whose principal activities are the design and manufacture of medical devices and exploiting the value of its IP and know-how.

RUA Life Sciences plc is incorporated and domiciled in the UK and its registered office is c/o Davidson Chalmers Stewart LLP, 163 Bath Street, Glasgow, G2 4SQ.

Basis of preparation

These condensed consolidated interim financial statements are for the six months ended 30 September 2021 and have been prepared with regard to the requirements of IAS 34 on "Interim Financial Reporting". They do not include all of the information required for full financial statements and should be read in conjunction with the audited consolidated financial statements of the Group for the year ended 31 March 2021.

The financial information for the six months ended 30 September 2021 and the comparative figures for the six months ended 30 September 2020 are unaudited. They have been prepared on the basis of the accounting policies set out in the consolidated financial statements of the Group for the year ended 31 March 2021 and, on the recognition, and measurement principles of IFRS in issue as effective at 30 September 2021. The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these condensed consolidated interim financial statements.

The figures for the year ended 31 March 2021 have been extracted from the audited statutory accounts which were approved by the Board of Directors on 9 July 2021, prepared under IFRS, received an unqualified audit report, did not contain statements under sections 498(2) and 498(3) of the Companies Act 2006 and have been delivered to the Registrar of Companies.

These condensed consolidated interim financial statements were approved for issue by the Board of Directors on 15 December 2021.

Going concern

The Group will continue to incur further costs as it continues to commercialise its vascular business and continues to pursue its polymeric heart valve through clinical development. After making enquiries, and assuming anticipated cash flows, the Directors expect that the Group's current financial resources will be sufficient to support operations for at least the next 12 months from the date of this announcement. The Group therefore continues to adopt the going concern basis in the preparation of these financial statements.

Loss per share

Loss per share has been calculated on the basis of the result for the period after tax, divided by the number of ordinary shares in issue in the period of 22,184,798. The 30 September 2020 comparative is calculated by reference to the number of ordinary shares in issue at that date which was 16,186,608. The comparative for the year ended 31 March 2021 is calculated by reference to the weighted average number of ordinary shares in issue which were 17,697,120.

   2.   RELATED PARTY TRANSACTION 

At 31 March 2021, the Group had a liability to David Richmond, Group CEO at that date, in respect of deferred consideration to the sum of GBP425,000 for the acquisition of RUA Medical Limited on 1 April 2020. The deferred consideration was settled on 30 April 2021. No interest was payable on the outstanding balance.

David Richmond resigned as a Director of the Company on 31 August 2021.

   3.   SEGMENTAL REPORTING 

The principal activities of the RUA Life Sciences Group are the design and manufacture of medical devices and exploiting the value of its IP and know-how.

 
 
 Analysis of revenue by income                        Unaudited    Unaudited                       Audited 
  stream 
                                                     Six months   Six months                 Twelve months 
                                                      to 30 Sep    to 30 Sep                     to 31 Mar 
                                                           2021         2020                          2021 
                                                       GBGBP000     GBGBP000                      GBGBP000 
 Contract Design & Development                               44            -                            23 
 Medical Devices Manufacture 
  & Sales                                                   508          416                           998 
 Royalty revenue                                            156          215                           507 
                                               ----------------  -----------  ---------------------------- 
 Total                                                      708          631                         1,528 
                                               ----------------  -----------  ---------------------------- 
 
 
  Analysis of revenue by geographical 
  location                                            Unaudited    Unaudited                       Audited 
                                                     Six months   Six months                 Twelve months 
                                                      to 30 Sep    to 30 Sep                     to 31 Mar 
                                                           2021         2020                          2021 
                                                       GBGBP000     GBGBP000                      GBGBP000 
 Europe                                                      43           79                           249 
 USA                                                        643          533                         1,237 
 RoW                                                         22           19                            42 
                                               ----------------  -----------  ---------------------------- 
 Total                                                      708          631                         1,528 
                                               ----------------  -----------  ---------------------------- 
 The Group's revenue for six months to 30 September 2021 is 
  segmented as follows: 
                                                      Unaudited                  Unaudited       Unaudited 
 Analysis of revenue by income                         RUA Life                RUA Medical 
  stream                                               Sciences                    Devices     Group Total 
 
 Contract Design & Development                                -                         44              44 
 Medical Devices Manufacture & 
  Sales                                                       -                        508             508 
 Royalty revenue                                            156                          -             156 
                                               ----------------  -------------------------  -------------- 
 Total                                                      156                        552             708 
                                               ----------------  -------------------------  -------------- 
 
 Analysis of revenue by geographical 
  location 
 Europe                                                       -                         44              44 
 USA                                                        134                        508             642 
 RoW                                                         22                          -              22 
                                               ----------------  -------------------------  -------------- 
 Total                                                      156                        552             708 
                                               ----------------  -------------------------  -------------- 
                                                      Unaudited                  Unaudited         Unaudited 
 Segment Analysis                                      RUA Life                RUA Medical             Total 
                                                       Sciences                    Devices 
                                                       GBGBP000                   GBGBP000          GBGBP000 
 
 Consolidated group revenues 
  from external customers                                   156                        552               708 
 Contributions to group operating 
  loss                                                    (967)                      (339)           (1,306) 
 Depreciation                                                 1                        117               118 
 Amortisation of intangible 
  assets                                                      5                         22                27 
 Segment assets                                           5,122                      3,763             8,885 
 Segment liabilities                                        259                      1,363             1,622 
 Intangible assets - goodwill                                 0                        301               301 
 Other intangible assets                                     85                        462               547 
 Additions to non-current assets                             84                        313               397 
 
 
   4.     GOODWILL 

The final valuation following the acquisition of RUA Medical Devices Limited gave rise to adjustments being required to the value of intangibles recognised in the Interim Report for the six months ended 30 September 2020 (as noted in note 5 below), and led to the following goodwill being recognised:

No impairment review has been carried out in the six-month period.

 
 
                                       GBGBP000 
  Gross carrying amount 
  Balance at 31 March 2020                    - 
  Acquired through business 
   combination                              301 
                              ----------------- 
  Balance at 31 March 2021                  301 
                              ----------------- 
  Impairment                                  - 
                              ----------------- 
  Balance at 30 September 
   2021                                     301 
                              ----------------- 
 
 
   5.     INTANGIBLE ASSETS 
 
                   Acquired 
               Intellectual           Development  Intellectual               Customer           Technology 
                   Property                 costs      property                related                based       Total 
 
Gross 
carrying 
amount 
At 31 March 
 2020                     -                   337         3,325                      -                    -       3,662 
Additions               834                     -             -                      -                    -         834 
               ------------  --------------------  ------------  ---------------------  -------------------  ---------- 
At 30 
 September 
 2020                   834                   337         3,325                      -                    -       4,496 
Adjustment 
 following 
 fair value 
 exercise 
 on 
 aquisition           (834)                     -             -                    247                  141       (446) 
Additions                 -                     -             -                      -                    -           - 
               ------------  --------------------  ------------  ---------------------  -------------------  ---------- 
At 31 March 
 2021                     -                   337         3,325                    247                  141       4,050 
Additions                 -                     -             -                      -                    -           - 
               ------------  --------------------  ------------  ---------------------  -------------------  ---------- 
At 30 
 September 
 2021                     -                   337         3,325                    247                  141       4,050 
               ------------  --------------------  ------------  ---------------------  -------------------  ---------- 
 
Amortisation 
and 
impairment 
At 31 March 
 2020                     -                   316         3,091                      -                    -       3,407 
Charge for 
 the period              62                    14             -                      -                    -          76 
               ------------  --------------------  ------------  ---------------------  -------------------  ---------- 
At 30 
 September 
 2020                    62                   330         3,091                      -                    -       3,483 
Adjustment 
 following 
 fair value 
 exercise 
 on 
 aquisition            (62)                     -             -                     14                    7        (41) 
Charge for 
 the period               -                     4             8                     15                    7          34 
               ------------  --------------------  ------------  ---------------------  -------------------  ---------- 
At 31 March 
 2021                     -                   334         3,099                     29                   14       3,476 
Charge for 
 the period               -                     2             4                     14                    7          27 
               ------------  --------------------  ------------  ---------------------  -------------------  ---------- 
At 30 
 September 
 2021                     -                   336         3,103                     43                   21       3,503 
               ------------  --------------------  ------------  ---------------------  -------------------  ---------- 
 
Net book 
value 
At 30 
 September 
 2020                   772                     7           234                      -                    -       1,013 
               ------------  --------------------  ------------  ---------------------  -------------------  ---------- 
At 31 March 
 2021                     -                     3           226                    218                  127         574 
               ------------  --------------------  ------------  ---------------------  -------------------  ---------- 
At 30 
 September 
 2021                     -                     1           222                    204                  120         547 
               ------------  --------------------  ------------  ---------------------  -------------------  ---------- 
 
   6.   PROPERTY, PLANT AND EQUIPMENT 
 
                               Land &          Plant       Office       Motor      Total 
                            Buildings    & Machinery    Equipment    Vehicles 
                             GBGBP000       GBGBP000     GBGBP000    GBGBP000   GBGBP000 
 Cost 
 At 31 March 2020                   -              -            6           -          6 
 Acquisition through 
  business combination 
  at fair value                   590            753           44           -      1,387 
 Additions                        211            118            -           -        329 
                          -----------  -------------  -----------  ----------  --------- 
 At 30 September 2020             801            871           50           -      1,722 
 Adjustment following 
  fair value exercise            (11)             12            -           -          1 
 Additions                        154            312           14          28        508 
 Disposals                          -           (81)          (1)           -       (82) 
                          -----------  -------------  -----------  ----------  --------- 
 At 31 March 2021                 944          1,114           63          28      2,149 
 Additions                         28            361            8           -        397 
 At 30 September 2021             972          1,475           71          28      2,546 
                          -----------  -------------  -----------  ----------  --------- 
 
 Depreciation 
 At 31 March 2020                   -              -            1           -          1 
 Charge                            28             55            8           -         91 
                          -----------  -------------  -----------  ----------  --------- 
 At 30 September 2020              28             55            9           -         92 
 Adjustment following 
  fair value exercise               1              5            -           -          6 
 Charge                            29             60           10           9        108 
 Eliminated on disposal             -            (8)          (1)           -        (9) 
                          -----------  -------------  -----------  ----------  --------- 
 At 31 March 2021                  58            112           18           9        197 
 Charge                            29             79            7           3        118 
 At 30 September 2021              87            191           25          12        315 
                          -----------  -------------  -----------  ----------  --------- 
 
 Net book value 
 At 30 September 2020             773            816           41           -      1,630 
                          -----------  -------------  -----------  ----------  --------- 
 At 31 March 2021                 886          1,002           45          19      1,952 
                          -----------  -------------  -----------  ----------  --------- 
 At 30 September 2021             885          1,284           46          16      2,231 
                          -----------  -------------  -----------  ----------  --------- 
 

Included in the net carrying amount of property plant and equipment are right-of-use assets as follows:

 
                       30 September 
                               2021 
                           GBGBP000 
 
 Plant & Machinery              147 
 Motor vehicles                  16 
                      ------------- 
 Total right-of-use 
  assets                        163 
                      ------------- 
 

7. ISSUED SHARE CAPITAL

During the 6 month period to 30 September 2021 the Company completed the Buy Back of all of its Deferred Shares, details of which were set out in the Circular sent to Shareholders dated 4 June 2021. All of the Deferred Shares acquired have been cancelled. Following the repurchase and cancellation of the Deferred Shares, there are no Deferred Shares in issue and the New Articles have been adopted.

The Company's issued share capital following completion of the Buy Back of all of its Deferred Shares comprises 22,184,798 Ordinary Shares of which none are held in treasury.

8. INTERIM ANNOUNCEMENT

The interim results announcement was released on 16 December 2021. A copy of this Interim Report is also available on the Company's website www.rualifesciences.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IR FFEFAIEFSEDE

(END) Dow Jones Newswires

December 16, 2021 02:00 ET (07:00 GMT)

Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De May 2022 a Jun 2022 Haga Click aquí para más Gráficas Rua Life Sciences.
Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De Jun 2021 a Jun 2022 Haga Click aquí para más Gráficas Rua Life Sciences.